|
US2015315179A1
|
|
Compounds and methods of treating neurological disorders
|
|
EP2588211A2
|
|
Env trimer immunogens
|
|
US2010080784A1
|
|
Methods for treating cachexia and lymphopenia
|
|
WO2009097296A1
|
|
Method of screening for metabolite transport modifiers
|
|
WO2007136518A2
|
|
Treatment of autoimmune disorders
|
|
CA2623946A1
|
|
Sulfatides for treatment of autoimmune disorders
|
|
US2005119176A1
|
|
Methods and compositions for derepression of IAP-inhibited caspase
|
|
AU2003261254A8
|
|
Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
|
|
US7262017B2
|
|
Diagnostic markers for ischemia
|
|
US6750030B2
|
|
Method of detecting cardiac ischemia using fatty acid binding protein
|
|
US6861523B2
|
|
1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries
|
|
US7229621B2
|
|
Method to enhance the immunogenicity of an antigen
|
|
US6545032B1
|
|
Synthesis of [3,5,7]-H-imidazo[1,5-a] imidazol-2(3H)-one compounds
|
|
US6441172B1
|
|
Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
|
|
US6210672B1
|
|
Topical immunostimulation to induce Langerhans cell migration
|
|
WO9716428A1
|
|
Isoquinoline derivatives and isoquinoline combinatorial libraries
|
|
WO9640208A1
|
|
Novel mu opioid receptor ligands: agonists and antagonists
|
|
WO9637212A1
|
|
POLYPEPTIDE COMPOUNDS THAT FORM β SHEETS
|
|
WO9710221A1
|
|
Synthesis of quinazolinone libraries
|
|
US5641861A
|
|
μopioid receptor ligands: agonists and antagonists
|
